Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
暂无分享,去创建一个
A. Pierini | E. Bargagli | I. Olivotto | M. Santoro | A. Coi | A. Vannucchi | R. Guerrini | M. Brunetto | F. Gorini | L. Mezzasalma | G. Castaman | M. Donati | S. Baldacci | S. Linari | P. Cameli | F. Cappelli | A. Sodi | Vittoria Murro | Alessandra Boncristiano | B. Coco | O. Rossi | P. Parronchi | B. Scappini | F. Pochiero
[1] E. Faqeih,et al. Long-term effectiveness of carglumic acid in patients with propionic acidemia (PA) and methylmalonic acidemia (MMA): a randomized clinical trial , 2021, Orphanet Journal of Rare Diseases.
[2] Minfeng Chen,et al. Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China , 2021, Orphanet Journal of Rare Diseases.
[3] M. Wack,et al. Assessing rare diseases prevalence using literature quantification , 2021, Orphanet Journal of Rare Diseases.
[4] M. Baumgartner,et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision , 2021, Journal of inherited metabolic disease.
[5] F. Bianchi,et al. Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy) , 2021, Orphanet Journal of Rare Diseases.
[6] H. Gurvit,et al. Neurological features and outcomes of Wilson’s disease: a single-center experience , 2021, Neurological Sciences.
[7] J. Ryan,et al. Management of Pulmonary Arterial Hypertension , 2020, Current Cardiovascular Risk Reports.
[8] V. Viprakasit,et al. Changing patterns in the epidemiology of β‐thalassemia , 2020, European journal of haematology.
[9] E. Santagostino,et al. WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] D. Franz,et al. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA). , 2020, Expert opinion on pharmacotherapy.
[11] H. Farkas,et al. Clinical characteristics and safety of plasma-derived C1-inhibitor therapy in children and adolescents with hereditary angioedema - a long-term survey. , 2020, The journal of allergy and clinical immunology. In practice.
[12] M. Czech,et al. A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries , 2020, Frontiers in Public Health.
[13] N. Dahms,et al. Progress in the understanding and treatment of Fabry disease. , 2020, Biochimica et biophysica acta. General subjects.
[14] V. Rubio,et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision , 2019, Journal of inherited metabolic disease.
[15] Christian Appenzeller‐Herzog,et al. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta‐analysis of controlled studies , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[16] C. Karaarslan. Leber’s Hereditary Optic Neuropathy as a Promising Disease for Gene Therapy Development , 2019, Advances in Therapy.
[17] A. Olry,et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database , 2019, European Journal of Human Genetics.
[18] M. Strek,et al. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat , 2019, Respiratory Research.
[19] B. Pemp,et al. Visual function in chronic Leber’s hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset , 2019, Graefe's Archive for Clinical and Experimental Ophthalmology.
[20] K. Kavaklı,et al. Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients , 2019, Turkish journal of haematology : official journal of Turkish Society of Haematology.
[21] Qijian Yi,et al. The Efficacy and Safety of Aerosolized Iloprost in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis , 2019, American Journal of Cardiovascular Drugs.
[22] E. Faqeih,et al. Evaluation of long-term effectiveness of the use of carglumic acid in patients with propionic acidemia (PA) or methylmalonic acidemia (MMA): study protocol for a randomized controlled trial , 2019, BMC Pediatrics.
[23] J. Vockley,et al. Phenylketonuria: Current Treatments and Future Developments , 2019, Drugs.
[24] M. Cicardi,et al. Current and emerging biologics for the treatment of hereditary angioedema , 2019, Expert opinion on biological therapy.
[25] L. Scott,et al. Migalastat: A Review in Fabry Disease , 2019, Drugs.
[26] Yi-min Cui,et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis , 2019, Orphanet Journal of Rare Diseases.
[27] D. Lacombe,et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients , 2019, Clinical Genetics.
[28] C. Belge,et al. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience , 2019, Therapeutic advances in respiratory disease.
[29] M. Svoboda,et al. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry , 2019, Respiratory Research.
[30] P. Striano,et al. The pharmacological management of Lennox-Gastaut syndrome and critical literature review , 2018, Seizure.
[31] Nicola Longo,et al. Hyperammonaemia in classic organic acidaemias: a review of the literature and two case histories , 2018, Orphanet Journal of Rare Diseases.
[32] G. Castaman. The benefits of prophylaxis in patients with hemophilia B , 2018, Expert review of hematology.
[33] A. Chakrapani,et al. Effect of carglumic acid with or without ammonia scavengers on hyperammonaemia in acute decompensation episodes of organic acidurias , 2018, Orphanet Journal of Rare Diseases.
[34] J. Barberà,et al. Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. , 2018 .
[35] R. Lockey,et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update , 2018, Allergy.
[36] Qijian Yi,et al. The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease , 2018, Medicine.
[37] M. Bhatt,et al. Advances in Treatment of Wilson Disease , 2018, Tremor and other hyperkinetic movements.
[38] G. Chandy,et al. Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson’s disease in resource constrained setting , 2018, Indian Journal of Gastroenterology.
[39] P. Striano,et al. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice. , 2018, Epileptic disorders : international epilepsy journal with videotape.
[40] Kathleen S. McGreevy,et al. Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta‐analysis , 2018, Epilepsia.
[41] D. Zafeiriou,et al. Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. , 2018, Blood cells, molecules & diseases.
[42] M. Porteus. Closing In on Treatment for Hemophilia B. , 2017, The New England journal of medicine.
[43] M. Manglani,et al. Management of ß-thalassemia – Consensus and controversies! , 2017 .
[44] T. Olson,et al. Diagnosis and Treatment of Aplastic Anemia , 2017, Current Treatment Options in Oncology.
[45] W. Aberer,et al. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. , 2017, The journal of allergy and clinical immunology. In practice.
[46] F. Bianchi,et al. Prevalence Estimates of Rare Congenital Anomalies by Integrating Two Population-Based Registries in Tuscany, Italy , 2017, Public Health Genomics.
[47] L. Peña-Quintana,et al. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives , 2017, Patient preference and adherence.
[48] N. Blau,et al. European guidelines for the diagnosis and management of patients with phenylketonuria , 2017 .
[49] G. Rücker,et al. Deferasirox for managing iron overload in people with thalassaemia. , 2017, The Cochrane database of systematic reviews.
[50] D. Hughes,et al. Affordable orphan drugs: a role for not‐for‐profit organizations , 2017, British journal of clinical pharmacology.
[51] B. Dumitriu,et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia , 2017, The New England journal of medicine.
[52] A. Bacigalupo. How I treat acquired aplastic anemia. , 2017, Blood.
[53] M. Falip,et al. Rufinamide in children and adults in routine clinical practice , 2017, Acta neurologica Scandinavica.
[54] G. Keating. Macitentan: A Review in Pulmonary Arterial Hypertension , 2016, American Journal of Cardiovascular Drugs.
[55] J. Palmblad,et al. Deferiprone‐induced agranulocytosis: 20 years of clinical observations , 2016, American journal of hematology.
[56] K. Lyseng-Williamson. Idebenone: A Review in Leber’s Hereditary Optic Neuropathy , 2016, Drugs.
[57] M. Couce,et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study , 2016, Orphanet Journal of Rare Diseases.
[58] H. Yoshinaga,et al. Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial , 2016, Epilepsy Research.
[59] P. Striano,et al. Treatment of Adults with Lennox–Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of Rufinamide , 2016, Neurology and Therapy.
[60] J. Granton,et al. Riociguat for the treatment of pulmonary hypertension , 2015, Expert review of respiratory medicine.
[61] R. Guerrini,et al. Antiepileptic Drug Treatment in Children with Epilepsy , 2015, CNS Drugs.
[62] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.
[63] A. Członkowska,et al. Early neurological worsening in patients with Wilson's disease , 2015, Journal of the Neurological Sciences.
[64] M. Balwani,et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial , 2015, The Lancet.
[65] P. L. McCormack. Eltrombopag: A Review of Its Use in Patients with Severe Aplastic Anaemia , 2015, Drugs.
[66] S. Rangarajan,et al. Pharmacokinetic and pharmacodynamic properties of plasma‐derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study , 2014, Journal of thrombosis and haemostasis : JTH.
[67] C. Mak,et al. Novel use of idebenone in Leber's hereditary optic neuropathy in Hong Kong. , 2014, Hong Kong medical journal = Xianggang yi xue za zhi.
[68] M. Morfini,et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. , 2014, Blood transfusion = Trasfusione del sangue.
[69] Anita MacDonald,et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia , 2014, Orphanet Journal of Rare Diseases.
[70] W. Lumry,et al. Repeat treatment of acute hereditary angioedema attacks with open‐label icatibant in the FAST‐1 trial , 2014, Clinical and experimental immunology.
[71] C. Vancheri,et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[72] R. Sussman,et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.
[73] A. Członkowska,et al. D‐penicillamine versus zinc sulfate as first‐line therapy for Wilson's disease , 2014, European journal of neurology.
[74] Jian Luo,et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. , 2014, Respiratory medicine.
[75] S. Xia,et al. Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassemia: A Meta-Analysis of 16 Randomized Controlled Trials , 2013, PloS one.
[76] T. Rossmanith,et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study , 2013, Transfusion.
[77] T. Machnig,et al. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[78] Z. Jing,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[79] A. Shapiro. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia , 2013, Expert opinion on biological therapy.
[80] Fei Tian,et al. Long-term effects of a combination of D-penicillamine and zinc salts in the treatment of Wilson’s disease in children , 2013, Experimental and therapeutic medicine.
[81] W. Aberer,et al. Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment , 2013, PloS one.
[82] Pedro Franco,et al. Orphan drugs: the regulatory environment. , 2013, Drug discovery today.
[83] N. Morrell,et al. Pathways in pulmonary arterial hypertension: the future is here , 2012, European Respiratory Review.
[84] Shigeo Hanada,et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.
[85] C. Hollak. An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease , 2012, Core evidence.
[86] Irena Melnikova,et al. Rare diseases and orphan drugs , 2012, Nature Reviews Drug Discovery.
[87] C. Town,et al. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[88] H. Nishiura,et al. Zinc Monotherapy From Time of Diagnosis for Young Pediatric Patients With Presymptomatic Wilson Disease , 2011, Journal of pediatric gastroenterology and nutrition.
[89] H. Leufkens,et al. No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study , 2009, Orphanet journal of rare diseases.
[90] G. Parenti. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics , 2009, EMBO molecular medicine.
[91] J. Vockley,et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. , 2009, The Journal of pediatrics.
[92] M. Bolli,et al. Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist , 2008, Journal of Pharmacology and Experimental Therapeutics.
[93] T. Beebe,et al. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. , 2008, Respiratory medicine.
[94] M. Schilsky,et al. Diagnosis and treatment of Wilson disease: An update , 2008, Hepatology.
[95] A. Chakrapani,et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study , 2007, The Lancet.
[96] A. Cavanna,et al. Psychopharmacology of topiramate: from epilepsy to bipolar disorder , 2006, Neuropsychiatric disease and treatment.
[97] R. Grymonpre,et al. Impact of Residence on Prevalence and Intensity of Prescription Drug Use Among Older Adults , 2006, The Annals of pharmacotherapy.
[98] Johny Verschakelen,et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.
[99] V. Krymskaya. Tumour suppressors hamartin and tuberin: intracellular signalling. , 2003, Cellular signalling.
[100] Ali I. Al-Gareeb,et al. Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia , 2017, Asian Journal of Transfusion Science.
[101] P. Maison-Blanche,et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. , 2017, European journal of internal medicine.
[102] A. Iorio,et al. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. , 2011, Blood transfusion = Trasfusione del sangue.
[103] S. Waisbren,et al. Phenylketonuria and BH4 deficiencies , 2010 .
[104] P A Dekker-de Kiefte,et al. Diagnosis and Treatment , 2020, Diabetes.